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Summary
 
Objective
 
Familial glucocorticoid deficiency type I (FGD1) is a
rare form of primary adrenal insufficiency resulting from recessive
mutations in the ACTH receptor (MC2R, 
 
MC2R
 
). Individuals with
this condition typically present in infancy or childhood with signs
and symptoms of cortisol insufficiency, but disturbances in the
renin-angiotensin system, aldosterone synthesis or sodium home-
ostasis are not a well-documented association of FGD1. As ACTH
stimulation has been shown to stimulate aldosterone release in
normal controls, and other causes of hyponatraemia can occur in
children with cortisol deficiency, we investigated whether 
 
MC2R
 
changes might be identified in children with primary adrenal failure
who were being treated for mineralocorticoid insufficiency.
 
Design
 
Mutational analysis of 
 
MC2R
 
 by direct sequencing.
 
Patients
 
Children (
 
n
 
 = 22) who had been diagnosed with salt-
losing forms of adrenal hypoplasia (19 isolated cases, 3 familial),
and who were negative for mutations in DAX1 (NR0B1) and SF1
(NR5A1).
 
Results
 
MC2R
 
 mutations were found in three individuals or
kindred (I: homozygous S74I; II: novel compound heterozygous
R146H/560delT; III: novel homozygous 579-581delTGT). These
changes represent severely disruptive loss-of-function mutations
in this G-protein coupled receptor, including the first reported
homozygous frameshift mutation. The apparent disturbances
in sodium homeostasis were mild, manifest at times of stress (e.g.
infection, salt-restriction, heat), and likely resolved with time.
 
Conclusions
 
MC2R
 
 mutations should be considered in children
who have primary adrenal failure with apparent mild disturbances
in renin-sodium homeostasis. These children may have been
misdiagnosed as having salt-losing adrenal hypoplasia. Making
this diagnosis has important implications for treatment, counselling
and long-term prognosis.
(Received 16 June 2006; returned for revision 18 July 2006; finally 
 
revised 18 August 2006; accepted 21 August 2006)
 
Introduction
 
Familial glucocorticoid deficiency type 1 (FGD1) (MIM: 202200) is
an autosomal recessive ACTH–resistance syndrome resulting from
mutations in the ACTH receptor (melanocortin-2 receptor, 
 
MC2R
 
[MIM: 607397]).
 
1,2
 
 The molecular basis of this condition was first
described in 1993 and, to date, approximately 20 different MC2R
mutations have been reported in around 40 individuals or families
with FGD1·
 
3–11
 
 The majority of MC2R mutations are homozygous
or compound heterozygous missense mutations that impair the
function of this G-protein coupled receptor to varying degrees.
 
10,11
 
To our knowledge, homozygous frameshift or nonsense mutations
in MC2R have not been described previously.
Children with FGD1 typically present with symptoms and signs
of glucocorticoid deficiency, such as prolonged jaundice, hypo-
glycaemia or hypoglycaemic convulsions, failure to thrive, hyper-
pigmentation and sepsis.
 
1,2
 
 Tall stature has also been reported in a
subset of individuals with FGD1, especially prior to glucocorticoid
treatment, but the pathogenic basis of this feature is not clear.
 
6,12
 
Disturbances in the renin-angiotensin system, mineralocorticoid
synthesis or sodium homeostasis are not a well-established feature
of this condition, and patients with classic FGD1 do not receive min-
eralocorticoid replacement. Nevertheless, the MC2R is expressed in
the zona glomerulosa of the adrenal gland, and acute administration
of ACTH(1–24) results in aldosterone release in normal human
volunteers.
 
13–15
 
 Thus, a facilitative role for ACTH in supporting
mineralocorticoid synthesis may be physiologically important,
perhaps during stress or in early life – a time of relative mineralo-
corticoid insensitivity.
 
16–19
 
 Furthermore, children with cortisol
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deficiency may be volume depleted if unwell, or may be prone to
hyponatraemia due to reduced free-water clearance, which might be
interpreted as a salt-losing state in the acute clinical scenario.
Here, we describe severe loss-of-function mutations in MC2R in
seven children from three kindred, several of whom had evidence of
disturbed renin-sodium homeostasis and were receiving mineralo-
corticoid replacement. These children were originally thought to
have a recessive form of primary adrenal hypoplasia. Thus, defining
the molecular basis of their condition has significant implications
for counselling, treatment and long-term prognosis.
 
Methods
 
Patients
 
A total of 22 individuals who had been diagnosed with likely
salt-losing forms of adrenal hypoplasia were included in the study.
Of these, 19 were isolated cases and 3 were familial cases. In all cases,
mutations in the nuclear receptors DAX1 (NR0B1) and steroidogenic
factor 1 (SF1, NR5A1) had been excluded, as well as obvious steroid
biosynthetic defects, metabolic and autoimmune disorders affecting
adrenal function, and adrenal haemorrhage.
 
Mutational analysis of MC2R
 
Following Institutional Board Approval and with informed consent,
genomic DNA was extracted from peripheral blood lymphocytes
and the entire coding region of 
 
MC2R
 
 (exon 2) was amplified using
variations on conditions reported previously.
 
3
 
 Polymerase chain
reaction (PCR) products were purified using 1 unit/ml Exonuclease
I (New England Biolabs, Hitchin, UK) and 0·1 unit/ml Shrimp Alkaline
Phosphatase (USB, Cleveland, OH, USA) and then subjected to
direct sequencing using BigDye terminator version 1·1 (Applied
Biosystems, Foster City, CA, USA) and a MegaBACE1000
 
TM
 
 cap-
illary DNA sequencer (Amersham Biosciences Inc., Little Chal-
font, UK). Sequence Analyser version 3·0 (Amersham Biosciences
Inc.) and Sequencher version 4·1 (Genecodes Corp., Ann Arbor, MI,
USA) were used to analyse the data.
 
Plasma renin activity assays
 
Plasma renin activity (PRA) was measured using several different
independently validated assays over this 15-year study period,
and are expressed as pmol angiotensin I/ml/h. In brief, PRA was
measured in Patient 1 by radioimmunoassay of angiotensin I using
a modification of an established method.
 
20
 
 Sensitivity of the assay
was 0·3 ng/ml/h, intra-assay coefficient of variation was 4·9% and
interassay coefficient of variance was 6·5%. PRA was measured in
Kindred 2 by the technique reported by Dillon 
 
et al
 
.
 
21
 
 A commercial
radioimmunoassay (RIA) (Adaltis, Casalecchio di Reno, Italy) was
used to measure PRA in Kindred 3.
 
Results
 
Kindred I (S74I)
 
Patient 1 is a female (46,XX) Causcasian child who presented with
a history of prolonged jaundice, poor weight gain and progressive
hyperpigmentation in the first three months of life. Initial investi-
gations revealed elevated ACTH, hypocortisolaemia and a sub-
optimal cortisol response to standard synacthen stimulation (Table 1).
Electrolytes were normal, but aldosterone was low for age and
Table 1. Clinical and biochemical data in patients with severe loss-of-function mutations in MC2R
Kindred Mutation
I 
S74I 
II 
R146H/560delT
III 
579–581delTGT
Patient Sex 1 Female 1 Male 2 Female 1 Male 2 Female 3 Female 4 Female
Age at presentation 3 months 19 months 12 months 2 months 4 days 1 day 1 day
Clinical presentation Pigmentation Pigmentation Pigmentation Pigmentation Pigmentation Pigmentation Pigmentation
Hypoglycaemia Hypoglycaemia Hypoglycaemia Hypoglycaemia Hypoglycaemia Hypoglycaemia Hypoglycaemia
Jaundice Convulsion Viral illness Convulsion Convulsion Family history Family history
ACTH (pmol/l) 302 – > 275 – – 440 210
(normal range) (< 10) (< 10) (< 10) (< 10)
Cortisol (nmol/l) (basal/peak) < 55/281 < 14/< 14 < 28/< 28a 33/10 < 14/< 14 56/45 < 14/19
PRA (pmol/ml/h) 24–30·3 3·2 1·4 13·5 – – –
(normal range for assay/age) (5·0–12) (0·1–2·0) (0·8–4·6) (5·0–12)
Aldosterone (pmol/l) 1052 – 86 1189 – – –
(normal range for age) (1000–4000) (500–1500) (1000–4000)
Sodium (mmol/l) 137 136 129 127 147 130 138
Potassium (mmol/l) 4·3 3·9 4·0 6·5 5·7 4·3 4·6
Treatment HC, FC HC, FC* HC, FC* HC, FC HC HC HC, FC
aPatient II.2 had a normal cortisol response to stimulation (peak, 769 nmol/l) at one month of age. HC, hydrocortisone; FC, fludrocortisone; 
FC*, fludrocortisone now withdrawn.
Conversion to SI units: ACTH, pmol/l × 4·54 for pg/ml; cortisol, nmol/l × 0·036 for µg/dl; plasma renin activity (PRA), pmol/ml/h × 1·30 for ng/ml/h; 
aldosterone, pmol/l × 0·036 for ng/dl.
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PRA was elevated. She was started on hydrocortisone replacement
at relatively high doses (15–20 mg/m
 
2
 
/day) but had persistently
elevated PRA and low aldosterone concentrations throughout early
childhood (Fig. 1). Consequently, 9
 
α
 
-fludrocortisone treatment was
started at 4 years of age, which resulted in a fall in renin activity.
Mutational analysis revealed a homozygous S74I missense mutation
in MC2R (Fig. 2). This mutation converts a highly conserved serine
to isoleucine within the second transmembrane domain of the
ACTH receptor. This change likely reduces ligand-binding affinity
and signal transduction, and has been shown to be associated with
marked loss of MC2R function in previous 
 
in vitro
 
 studies using
Y6 and OS3 cells.
 
10,11
 
Kindred II (R146H/560delT)
 
The second family are from Iran, with an affected boy and girl.
An older child had died at 18 months of age following a convulsion.
The proband (46,XY) presented with failure to thrive, hyper-
pigmentation and a hypoglycaemic convulsion at 19 months of age
in Iran. Cortisol was found to be low and he was started on methyl-
prednisolone. At 21 months of age he was transferred for further
investigation. Two days after stopping all treatment, there was no
cortisol increase following standard synacthen stimulation and basal
PRA was mildly elevated (Table 1). Serum 17-hydroxyprogesterone
(17-OHP) was not elevated. Given these findings
 
,
 
 he was diagnosed
as having adrenal hypoplasia and treated with hydrocortisone and
fludrocortisone throughout childhood. The fludrocortisone has
recently been stopped at the age of 14 and his PRA has remained
within normal limits over 18 months.
His sister’s karyotype is 46,XX. She was investigated at 1 month
of age on account of the family history. She had a normal cortisol
response to standard synacthen stimulation at one month of age
(peak 769 nmol/l), but became progressively pigmented throughout
the first year of life. Investigations at 12 months of age showed absent
cortisol response to synacthen stimulation and elevated ACTH. Her
aldosterone was low but PRA was not raised. Almost simultaneously,
she developed a severe viral illness and became hyponatraemic
(sodium 129 mmol/l). She was started on hydrocortisone and
received fludrocortisone treatment transiently.
Mutational analysis revealed compound heterozygous mutations
(R146H/560delT) in MC2R in both children (Fig. 2). The R146H
change affects a highly conserved arginine in the second intracellular
loop of the receptor. This mutation has been reported previously
Fig. 1 Patient 1 had low-normal aldosterone concentrations (upper panel) 
and persistently elevated plasma renin activity (PRA) (lower panel). The 
steroid replacement regimen is shown above. Shaded areas represent 
age-adjusted normal ranges for each assay. Recumbent measurements for 
PRA were taken after 2 years of age. Conversion: PRA, pmol/ml/h × 1·30 
for ng/ml/h; aldosterone, pmol/l × 0·036 for ng/dl.
Fig. 2 Pseudostructural plot of the ACTH 
receptor (MC2R) showing the position of some 
previously described mutations and a list of 
homozygous and compound heterozygous 
changes. Approximate number of individuals or 
families reported to have each individual mutation 
is shown in parentheses. Mutations found in the 
three individuals/kindred reported here (S74I; 
R146H/560delT; 579–581delTGT) are indicated 
in boxes.
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in a homozygous state in three patients, and was carried by the
mother. The arginine to histidine change likely affects the interaction
between the second cytoplasmic loop and fourth transmembrane
domain, resulting in severe loss of receptor function in Y6 cells
through impaired G-protein coupling and ligand binding.
 
10
 
 The
second change is a single nucleotide deletion at position 560 (560delT)
resulting in a frameshift and premature stop codon at amino acid
215. This novel change would be predicted to cause complete loss
of receptor function, and was carried by the father.
 
Kindred III (579–581delTGT)
 
The third family is a highly consanguineous kindred from Qatar.
Four of 12 children born in three nuclear families have primary
adrenal failure. The proband (46,XY) presented at 60 days of age
with pigmentation and a hypoglycaemic convulsion (Table 1). He
had an elevated PRA, his aldosterone was inappropriately low, and
he had mild hyponatraemia/hyperkalaemia. Thus, he was diagnosed
as having adrenal hypoplasia and treated with hydrocortisone and
fludrocortisone. The second child (46,XX) presented at 4 days of age
with a hypoglycaemic convulsion. She was hyperpigmented and
found to be profoundly hypocortisolaemic (< 14 nmol/l), and was
started on hydrocortisone alone. Given the emerging family history,
two further children were diagnosed as likely affected on the first day
of life on account of marked hyperpigmentation and hypoglycaemia,
and hydrocortisone was started almost immediately. One child was
also commenced on fludrocortisone as it was believed this family had
an autosomal recessive form of adrenal hypoplasia, and that treat-
ment should be started before the onset of a salt-losing crisis. Thus,
in all three cases, treatment was commenced within the first four days
of life before disturbances in PRA or salt balance would likely have
become manifest
 
.
 
Mutational analysis revealed a novel homozygous three-nucleotide
deletion (579–581delTGT) in all affected individuals. This deletion
results in a stop codon at position 193 (Y193X) in the fifth trans-
membrane domain of the ACTH receptor (Fig. 2). Their parents are all
carriers of this mutation and siblings are either heterozygous or normal.
 
Discussion
 
The clinical diagnosis of adrenal failure in infancy or childhood can
be challenging. Affected individuals often have an insidious clinical
course, and symptoms and signs can be nonspecific or subtle. Hyper-
pigmentation is often overlooked, and when a child presents collapsed
or with a hypoglycaemic convulsion, life-saving treatment must be
administered.
When the child has marked hyponatraemia, hyperkalaemia, in-
appropriately high urinary sodium excretion and a reduced circulating
volume, the diagnosis of salt-losing primary adrenal failure is usually
clear. Such salt-losing forms of adrenal insufficiency causing com-
bined glucocorticoid and mineralocorticoid insufficiency can occur in
several well-defined conditions, such as defects in steroidogenesis
(e.g. steroidogenic acute regulatory protein (STAR), CYP11A1, HSD3B2,
CYP21), following adrenal destruction (e.g. haemorrhage, adreno-
leukodystrophy, autoimmune), or with forms of congenital adrenal
hypoplasia (e.g. X-linked (DAX1), steroidogenic factor-1, IMAGe).
 
22,23
 
However, if biochemical findings are subtle (e.g. mild hypo-
natraemia with borderline high potassium), or if the child has
already received fluid resuscitation and steroid treatment, dissecting
out the exact biochemical nature of the condition at a later date can
be difficult.
The association of salt-losing states or apparent mineralocorticoid
insufficiency with forms of familial glucocorticoid deficiency/ACTH
resistance syndromes is less clear. Spark 
 
et al
 
. reported an impaired
aldosterone response to ACTH stimulation in a patient with FGD,
but the molecular diagnosis is not reported.
 
24
 
 Furthermore, this
patient presented in childhood with isolated glucocorticoid insuffi-
ciency, no clinical disturbances in the renin-angiotensin-aldosterone
pathway were ever detected, and an impairment of aldosterone
response to ACTH stimulation was only evident in the recumbent
setting when the individual was assessed in early adulthood. In
addition, Davidai 
 
et al
 
. described mild disturbances in the renin-
angiotensin system in a patient with FGD.
 
25
 
 However, a MC2R
mutation causing FGD1 in this individual has now been excluded
(Z. Hochberg, personal communication). Thus, although it is known
that approximately 10–15% of individuals who have ACTH resistance
as part of the Triple A (Allgrove) syndrome (AAAS, ALADIN)
(OMIM: 231550) do have evidence of mineralocorticoid deficiency,
 
26
 
disturbances in renin-sodium homeostasis in patients with other
ACTH-resistance syndromes (FGD1 due to MC2R mutations; FGD2
due to mutations in MRAP [607398]) are not well established.
 
27
 
In normal physiological states, angiotensin II is the major drive
to mineralocorticoid production. However, the ACTH receptor is
expressed in the zona glomerulosa of the adrenal gland, and acute
administration of synacthen to normal individuals produces a rapid
and dose-dependent rise in serum aldosterone.
 
13–15
 
 Thus, ACTH
may have an important facilitative role stimulating mineralocorti-
coid synthesis and release, and functional studies have shown that
the CYP11B2 minimal promoter is cAMP responsive.
 
28
 
 This facili-
tative effect of ACTH on mineralocorticoid release may be most
important during times of acute stress (e.g. illness, heat, convulsion),
salt-deprivation (e.g. breastfeeding), or when there is relative min-
eralocorticoid insensitivity (e.g. early infancy). Consequently, one
might expect ACTH resistant states to be associated with some dis-
turbance in renin-sodium homeostasis. However, this is not well
established in FGD1, as the changes described previously are often
homozygous or compound heterozygous missense changes in MC2R
that have some limited residual activity.
 
10,11
 
The individuals described here likely represent the most severe end
of the spectrum of FGD1, and include a family who are homozygous
for a severely disruptive frameshift mutation in the receptor (579–
581delTGT leading to a stop codon at 193). In this kindred, the
proband presented with a hypoglycaemic convulsion and hyper-
pigmentation at 60 days of age. Subsequent affected individuals were
diagnosed in the first four days of life on account of marked hyper-
pigmentation and hypoglycaemia, before the usual onset of salt loss
or when biochemical evidence of salt loss might be manifest
 
.
 
 Given
the family history, steroid replacement was started immediately, and
one child received fludrocortisone as it was felt the family had a reces-
sive form of adrenal hypoplasia. In kindred II (R146H/560delT), the
proband presented with a hypoglycaemic convulsion at 19 months
of age, after an insidious period of failure to thrive. The elevated
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renin led to a diagnosis of adrenal hypoplasia, and it was considered
necessary to add fludrocortisone treatment to the glucocorticoid
replacement. Of note, his younger sister has a very adequate cortisol
response to synacthen stimulation at one month of age, but was
profoundly cortisol deficient by one year. She was found to be
hyponatraemic when she presented with a respiratory viral illness.
As her plasma renin activity was low, the low sodium could have been
due to inappropriate ADH release or an inability to excrete a water
load due to hypocortisolaemia. However, in the clinical context and
with the family history, it was felt that she had a possible salt-losing
form of adrenal hypoplasia. Finally, Patient 1 – who harbours a severe
loss-of-function missense mutation (S74I) – had long-standing
evidence of subtle disturbances in renin-aldosterone and was even-
tually commenced on fludrocortisone replacement at 4 years of age
(Fig. 1) as it was felt she had a subtle form of adrenal hypoplasia.
This S74I mutation is one of the more frequent mutations reported
in MC2R and has been reported in approximately 10 patients
previously.
 
2
 
 To our knowledge, none of these other patients have
received mineralocorticoid replacement.
Taken together, these cases highlight that severe loss-of-function
mutations in MC2R may be found in a significant proportion of
children with primary adrenal insufficiency and who have been
diagnosed as having salt losing forms of adrenal hypoplasia. These
findings may suggest a supportive role for ACTH in mineralocorti-
coid synthesis and release, especially in times of stress, salt-restriction
or relative mineralocorticoid insensitivity. In other situations,
hyponatraemia may reflect inappropriate ADH release or relative
water overload following infection or convulsions, especially in a
glucocorticoid deficient state. As biochemical data are often limited
in the acute clinical situation, and the emphasis is on saving the
child’s life, it is possible that many more children with sporadic or
familial forms of adrenal disease have been labelled as having adrenal
hypoplasia or related conditions, whereas the true pathology lies
in the MC2R. This study highlights the importance of obtaining
accurate data on plasma renin activity, aldosterone and salt balance
in all infants and children diagnosed with primary adrenal failure,
with particular attention being paid to assay- and age-specific normal
ranges. Making the correct diagnosis has important implications for
counselling and long-term management
 
.
 
 Mineralocorticoid require-
ments often decrease with age, as evidenced from the fall in normal
mineralocorticoid secretion rates after infancy and from the bio-
chemical improvement throughout childhood seen in children
with autosomal dominant pseudohypoaldosteronism type I due to
mutations in the mineralocorticoid receptor. Thus, infants or young
children who appear to have salt loss should be started on fludro-
cortisone replacement, especially if there is persistently elevated
PRA, urinary sodium loss, salt craving or poor growth, or if these
parameters are not normalized on a standard regimen of glucocor-
ticoid replacement alone. However, it might be predicted that, with
careful monitoring, these children could be weaned off their fludro-
cortisone supplements eventually, or at least to reserve them for
times of stress or potential volume depletion. This situation contrasts
with individuals with X-linked adrenal hypoplasia who are likely to
require mineralocorticoid replacement for life. Finally, the normal
cortisol response to synacthen stimulation in a one-month-old
sibling, followed by profound cortisol insufficiency at one year of
age, shows that FGD1 may be a clinically progressive condition, and
ongoing clinical vigilance or molecular analysis are needed in
relatives even if physiological tests of cortisol reserve are initially
normal.
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